Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

GenomSys S.A.. (9/16/19). "Press Release: GenomSys, the Swiss Startup Disrupting Genomics Information Handling Closes a CHF 9.3 Million Series A Investment Round".

Organisations Organisation GenomSys S.A.
  Organisation 2 Preon Capital (family office of Jari Ovaskainen)
Products Product data storage (technology + s/w)
  Product 2 venture capital
Index term Index term GenomSys–SEVERAL: investment, 201909 financing round Series A CHF9.3m led by Preon Capital
Persons Person Alberti, Claudio (GenomSys 201909 CTO + Co-Founder)
  Person 2 Levensohn, Pascal (Dolby Family Ventures 201909 Managing Director + Susman Ventures 201909 Managing Director)

GenomSys is proud to announce the successful finalization of the series A investment round.

GenomSys, a software company which develops ISO compliant technology for efficient processing and sharing of DNA data, announced it has completed its series A investment round. The company raised CHF 9.3 million in this financing, driven by the accelerating development progress of its MPEG-G-based solution for DNA data processing.

The Series A round was led by Preon Capital, the Geneva-based family office of Jari Ovaskainen, Europe’s 2014 Business Angel of the year. Preon was joined by a group of European and U.S. investors, including the Club degli Investitori – the most active business angel network in Italy , the Elysia Capital and Pygar family offices, linked respectively to the founder of the European unicorn Advanced Accelerator Applications and to the multinational diagnostic company Diasorin. U.S.-based investors Dolby Family Ventures and Susman Ventures participated in this financing. Pascal Levensohn, Managing Director of these funds, has joined the GenomSys board of directors.

Founded in 2016, GenomSys has developed technology facilitating access to highly-secured personalized medicine services. Its product portfolio includes solutions to compress, browse, store and share genomic information based on the model of digital media compression and streaming technology. Decreasing costs of genomic sequencing are enabling DNA analysis to become mainstream, promising wider accessibility for medical professionals to generate new perspectives. GenomSys’ solutions solve the associated challenges from the ever-increasing data volumes, format proliferation, storage costs and analytic complexity caused by this data explosion.

Based on the newly released ISO MPEG-G Standard, GenomSys’ Software Suite “will bring a dramatic reduction in genomic files’ size, a faster information transfer and more efficient data analysis”, says Claudio Alberti, GenomSys’ co-founder.

As stated by the International Organization for Standardization (ISO), MPEG-G “provides the enabling technology that will allow the community to create an ecosystem of novel, interoperable, solutions in the field of genomic information processing”. MPEG-G will also bring genomic information to personal devices, which will accelerate individuals’ access to personalized medicine, while enforcing strict data-privacy standards.

About GenomSys

GenomSys is a Swiss company developing ISO compliant, enterprise-grade tools and applications for efficient processing and sharing of DNA data, enabling the progress of large-scale genomics and personalized medicine. GenomSys offers solutions to securely compress, browse and store individual DNA on any devices and share them with practitioners for diagnostics, pharmacogenomics, personalized treatments, etc.

For more information, visit our website


Raphaël Bernard
Marketing & Communication Manager
GenomSys SA

Record changed: 2020-02-08


Picture ConsulTech GmbH RnD Credit Germany 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top